Market Overview

Why Lannett Shares Are Down More Than 16%

Related LCI
A Peek Into The Markets: U.S. Stock Futures Edge Higher Ahead Of Economic Reports, Fed Speakers
Earnings Scheduled For August 23, 2017
Dow Leads Stocks As Indexes Crawl To Record Highs Again (Investor's Business Daily)

Shares of Lannett (NYSE: LCI) are down more than 16 percent following a research note from Roth Capital.

Generic drugmaker Impax Laboratories (NASDAQ: IPXL) has come under fire for price fixing of Digoxin, a drug that Lannett also produces. According to the Roth Capital note, Lannett may also get a subpoena. This would be very damaging for the stock, as Digoxin makes up approximately 23 percent of sales.

Related Link: Exclusive: Bio-Techne Executive On M&A Possibilities

The Roth note also commented that the generic drug space may not be sustainable in the long run.

These comments come despite Roth’s Buy rating and $45 price target. Shares of Lannett were last down 16.5 percent to $39.30.

Latest Ratings for LCI

Aug 2017Deutsche BankMaintainsHold
Jul 2017Deutsche BankMaintainsHold
Aug 2016Raymond JamesMaintainsOutperform

View More Analyst Ratings for LCI
View the Latest Analyst Ratings

Posted-In: Roth CapitalAnalyst Color Analyst Ratings


Related Articles (LCI + IPXL)

View Comments and Join the Discussion!

Partner Center